Invivyd Inc (IVVD)

Apr 9, 2026, 10:07 AM EDT - 4 hours ago

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Apr 9, 2026, 7:01 AM EDT - 7 hours ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Apr 6, 2026, 7:01 AM EDT - 3 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 30, 2026, 4:05 PM EDT - 9 days ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 5, 2026, 7:03 AM EST - 5 weeks ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:01 AM EST - 5 weeks ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 2, 2026, 4:10 PM EST - 5 weeks ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Feb 24, 2026, 7:01 AM EST - 6 weeks ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Feb 3, 2026, 7:01 AM EST - 2 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Jan 20, 2026, 7:01 AM EST - 2 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 8, 2026, 7:01 AM EST - 3 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Dec 23, 2025, 7:05 AM EST - 3 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 3 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Nov 25, 2025, 7:01 AM EST - 4 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 7:01 AM EST - 4 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 18, 2025, 8:23 AM EST - 5 months ago

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HD HP

Nov 17, 2025, 10:40 PM EST - 5 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 4:01 PM EST - 5 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Nov 6, 2025, 7:01 AM EST - 5 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 4:01 PM EST - 5 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Oct 28, 2025, 7:01 AM EDT - 5 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 6 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Sep 24, 2025, 4:01 PM EDT - 7 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Sep 17, 2025, 7:01 AM EDT - 7 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 4, 2025, 7:01 AM EDT - 7 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Aug 27, 2025, 7:01 AM EDT - 8 months ago

Invivyd to Participate in Upcoming Investor Conferences

Aug 22, 2025, 12:00 PM EDT - 8 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 20, 2025, 11:58 PM EDT - 8 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 18, 2025, 4:32 PM EDT - 8 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 14, 2025, 4:49 PM EDT - 8 months ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:47 PM EDT - 8 months ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Jul 23, 2025, 7:01 AM EDT - 9 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 21, 2025, 7:05 AM EDT - 9 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 2, 2025, 7:01 AM EDT - 10 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 11 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 15, 2025, 7:01 AM EDT - 11 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 11 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 11 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 11 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 8, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Apr 21, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025, 4:15 PM EDT - 1 year ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 20, 2025, 8:01 AM EDT - 1 year ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 5, 2025, 7:05 AM EST - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025, 9:20 AM EST - 1 year ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 1 year ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 10, 2025, 7:00 AM EST - 1 year ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025